UNSPSC 51202502: Mizoribine

This classification denotes an immunosuppressant with the molecular formula C9H13N3O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 4JR41A10VP, chemically known as 1h-imidazole-4-carboxamide, 5-hydroxy-1-.beta.-d-ribofuranosyl- but more generally known as mizoribine, which bears US NIH Compound Identifier 4213. European Medicines Agency schedules Mizoribine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09019MIG. The term MIZORIBINE is an International Non-Proprietary Name.

UNSPSC 51202502 Mizoribine is a Commodity code for a specific immunosuppressant pharmaceutical product, but recent state and local procurement activity shows minimal direct solicitation under this code. The single recent opportunity nominally tagged to this code—Seminole County, Florida's IFB for Naloxone and Safe Drug Deactivation Systems (IFB60459723LAS, due July 26, 2023)—is unrelated to mizoribine; it addresses opioid-overdose response and drug disposal, not immunosuppression. State and local governments that do procure mizoribine typically source it through pharmacy benefit programs, cooperative purchasing alliances, and generic pharmaceutical contracts rather than through standalone commodity solicitations tagged to this specific code.

Recent state and local pharmaceutical procurement activity in the broader immunosuppressant and generic drug space shows issuing bodies concentrated in state health agencies and cooperative purchasing organizations. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products serving state and local government facilities across multiple states including Oregon. The Texas Health and Human Services Commission released an RFI (HHS0017013, due April 3, 2026) to explore direct-to-manufacturer prescription programs. The City of Tampa solicited medical and first aid supplies (26P00145, due March 13, 2026) for its Fire Department, estimated at $700,000, designated as a sheltered market opportunity for certified Small Local Business Enterprises with a 5 percent bid discount. Activity clusters in large state agencies managing pharmacy benefits and cooperative purchasing vehicles rather than in individual jurisdictions, with the strongest recent concentration in Minnesota and Texas state procurement offices. The code shows limited standalone procurement activity; mizoribine acquisition typically embeds within broader generic pharmaceutical contracts or state health-system formulary management rather than appearing as a discrete commodity solicitation.